HPS2-THRIVE and the future of clinical endpoint trials
Prof.John Betteridge with a critical appraisal of the results of the HPS2-THRIVE trial and the relevance for clinical practice and design of future outcome trials.
Prof. D John Betteridge
Professor Emeritus of Endocrinology and Metabolism
University College London and Associate Dean, Royal Society of Medicine
London, United Kingdom
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.